ArticleCancers2022

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.

Beom Kyung Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.